Prime Medicine (NYSE:PRME) is a clinical‐stage biotechnology company focused on developing next‐generation gene editing therapeutics using its proprietary prime editing platform. Founded in 2021 by leading scientists from the Broad Institute, Prime Medicine aims to expand the scope, precision and efficiency of genetic medicines to address a broad array of serious diseases. The company is headquartered in Cambridge, Massachusetts, where it is advancing its research and early clinical programs.
The core of Prime Medicine’s technology is prime editing, a versatile approach that enables targeted insertions, deletions and base swaps in DNA without relying on double‐strand breaks or donor DNA templates. Leveraging this platform, the company is developing therapies for genetically defined diseases across multiple therapeutic areas, including rare inherited disorders, oncology and metabolic conditions. Prime Medicine’s pipeline features both in vivo and ex vivo candidates designed to correct disease‐causing mutations at the molecular level.
To accelerate its programs, Prime Medicine has entered into strategic collaborations and licensing agreements with global pharmaceutical and academic partners. These partnerships bolster its capabilities in vector design, manufacturing scale‐up and clinical development. By combining internal expertise with external resources, the company aims to streamline the path from discovery through regulatory submission.
Prime Medicine serves patients worldwide through its U.S. operations and collaborative networks in Europe and Asia. Its leadership team comprises seasoned executives in biotechnology, drug development and regulatory affairs, supported by a scientific advisory board of renowned gene editing researchers. With a commitment to innovation and rigorous development practices, Prime Medicine seeks to translate breakthrough science into transformative therapies.
